Compare DLO & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLO | TFX |
|---|---|---|
| Founded | 2013 | 1943 |
| Country | Uruguay | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 5.4B |
| IPO Year | 2021 | N/A |
| Metric | DLO | TFX |
|---|---|---|
| Price | $14.29 | $121.31 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 10 | 10 |
| Target Price | $15.80 | ★ $139.88 |
| AVG Volume (30 Days) | ★ 990.6K | 714.4K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.61% | 1.11% |
| EPS Growth | ★ 40.60 | N/A |
| EPS | ★ 0.56 | N/A |
| Revenue | $960,191,000.00 | ★ $3,189,988,000.00 |
| Revenue This Year | $41.56 | $9.90 |
| Revenue Next Year | $30.87 | $10.51 |
| P/E Ratio | $25.25 | ★ N/A |
| Revenue Growth | ★ 31.63 | 5.42 |
| 52 Week Low | $7.61 | $102.58 |
| 52 Week High | $16.78 | $185.94 |
| Indicator | DLO | TFX |
|---|---|---|
| Relative Strength Index (RSI) | 57.99 | 51.20 |
| Support Level | $14.09 | $120.31 |
| Resistance Level | $14.45 | $123.55 |
| Average True Range (ATR) | 0.35 | 2.70 |
| MACD | 0.03 | -0.51 |
| Stochastic Oscillator | 76.11 | 21.64 |
DLocal Ltd is focused on making the complex simple, redefining the online payment experience in emerging markets. Through its technology platform, One dLocal, the company enables world-wide enterprise merchants to get paid (pay-in) and to make payments (pay-out) online in a safe and efficient manner. The company earns revenue from fees charged to merchants in connection with payment processing services for cross-border and local payment transactions. The company's geographical segments include Latin America and Non-Latin America with a majority of its revenue being generated from Brazil in Latin America region.
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.